NCT00995202

Brief Summary

RATIONALE: Diagnostic procedures, such as ultrasound, x-ray, colonoscopy, CT scan, and CEA assessment, may help monitor a patient's response to surgery. It is not yet known which follow-up regimen is more effective in patients who have undergone surgery for colorectal cancer. PURPOSE: This randomized phase III trial is comparing two types of follow-up care with or without CEA assessments to see how well they work in patients who have undergone surgery for stage II or stage III colorectal cancer.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,997

participants targeted

Target at P75+ for phase_3 colorectal-cancer

Timeline
Completed

Started Sep 2009

Longer than P75 for phase_3 colorectal-cancer

Geographic Reach
3 countries

117 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2009

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

October 14, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 15, 2009

Completed
10.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2019

Completed
1.5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2021

Completed
Last Updated

December 7, 2021

Status Verified

December 1, 2021

Enrollment Period

10.3 years

First QC Date

October 14, 2009

Last Update Submit

December 6, 2021

Conditions

Keywords

stage II colon cancerstage II rectal cancerstage III colon cancerstage III rectal canceradenocarcinoma of the colonadenocarcinoma of the rectum

Outcome Measures

Primary Outcomes (1)

  • Overall survival rate

    Time between randomization and date of death (all causes)

    5 years

Secondary Outcomes (1)

  • Disease-free survival rate

    5 years

Study Arms (4)

Standard Monitoring CEA/ Standard Imagery

OTHER

No specific follow-up of CEA and Standard imagery

Procedure: Standard Monitoring CEAProcedure: Standard Monitoring Imagery

Intensive monitoring CEA/ Standard Imagery

OTHER

Intensive follow-up CEA and Standard imagery .

Procedure: Intensive Monitoring CEAProcedure: Standard Monitoring Imagery

Intensive Monitoring CEA / Intensive Monitoring Imagery

OTHER

Intensive follow-up CEA and Intensive imagery

Procedure: Intensive Monitoring CEAProcedure: Intensive Monitoring Imagery

Standard Monitoring CEA/ Intensive Monitoring Imagery

OTHER

No specific follow-up of CEA and Intensive Imagery

Procedure: Standard Monitoring CEAProcedure: Intensive Monitoring Imagery

Interventions

No specific follow-up of CEA

Standard Monitoring CEA/ Intensive Monitoring ImageryStandard Monitoring CEA/ Standard Imagery

CEA levels are measured every 3 months for 3 years, then every 6 months for 2 years.

Intensive Monitoring CEA / Intensive Monitoring ImageryIntensive monitoring CEA/ Standard Imagery

Abdominal ultrasound examination every 3 months during 3 years then every 6 months during 2 years then annually. Chest X-ray examination eveyr 6 months during 3 years then annually during 2 years

Intensive monitoring CEA/ Standard ImageryStandard Monitoring CEA/ Standard Imagery

Alternation every 3 months of TDM thoraco-abdomino-pelvis and abdominal ultrasound examination during 3 years and twice a year after during 2 years. Coloscopy at 3 years and then evry 5 years if normal

Intensive Monitoring CEA / Intensive Monitoring ImageryStandard Monitoring CEA/ Intensive Monitoring Imagery

Eligibility Criteria

Age18 Years - 120 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
DISEASE CHARACTERISTICS: * Pathologically confirmed adenocarcinoma of the colon or rectum * Stage II or III disease * No distant metastatic disease * Has undergone curative resection for no residual tumor * Carcinoembryonic antigen (CEA) ≤ 1.5 x upper limit of normal after surgery PATIENT CHARACTERISTICS: * WHO performance status 0-1 * Not pregnant or nursing * Fertile patients must use effective contraception * No inflammatory bowel disease * No other malignancy within the past 5 years except basal cell carcinoma of the skin and/or carcinoma in situ of the cervix * No genetic syndromes PRIOR CONCURRENT THERAPY: * See Disease Characteristics

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Study Sites (117)

Clinique Sud Luxembourg

Arlon, Belgium

Location

CH

Abbeville, France

Location

Clinique Isabelle

Abbeville, France

Location

CHU Nord

Amiens, France

Location

CHU

Angers, France

Location

CH

Antibes, France

Location

CH

Aubenas, France

Location

CH

Auch, France

Location

CH

Auxerre, France

Location

Polyclinique Ste Marguerite

Auxerre, France

Location

CH Henri Duffaut

Avignon, France

Location

Clinique Sainte Cahterine

Avignon, France

Location

Centre d'oncologie et de radiothérapie du Pays Basque

Bayonne, France

Location

CH

Beaune, France

Location

CH

Beauvais, France

Location

CHU J Minjoz

Besançon, France

Location

Centre de Radiothérapie et d'oncologie médicale

Béziers, France

Location

CH

Béziers, France

Location

CH

Blois, France

Location

CH

Bobigny, France

Location

Polyclinique Nord Aquitaine

Bordeaux, France

Location

CH Duchenne

Boulogne-sur-Mer, France

Location

CH

Bourg-en-Bresse, France

Location

Hôpital du Morvan

Brest, France

Location

CH

Briey, France

Location

CHIC

Castres, France

Location

CH

Challans, France

Location

Hôpital Sainte Marie

Chalon-sur-Saône, France

Location

CH

Chambéry, France

Location

Clinique du Cléret et Clinique Saint Joseph

Chambéry, France

Location

CH

Châlons-en-Champagne, France

Location

CH

Cholet, France

Location

CHU Estaing

Clermont-Ferrand, France

Location

Hôpital Pästeur

Colmar, France

Location

CH

Compiègne, France

Location

Clinique des 2 Caps

Coquelles, France

Location

Clinique des Cèdres

Cornebarrieu, France

Location

Clinique des Acacias

Cucq, France

Location

CH

Dax, France

Location

Cabinet d'HGE - Cours De Gaulle

Dijon, France

Location

Cabinet Privé Point Médical

Dijon, France

Location

Centre d'Oncologie Médicale du Parc

Dijon, France

Location

CHU le bocage

Dijon, France

Location

CH

Draguignan, France

Location

Clinique Saint Vincent

Épernay, France

Location

Centre médical de Forcilles

Férolles-Attilly, France

Location

CHI Saint Raphael

Fréjus, France

Location

CHI

Gap, France

Location

Institut Hollard

Grenoble, France

Location

CH

Haguenau, France

Location

CHD

La Roche-sur-Yon, France

Location

CH

Lagny-sur-Marne, France

Location

CH Louis Pasteur

Le Coudray, France

Location

CH

Le Havre, France

Location

CH

Le Mans, France

Location

Hôpital Robert Boulin

Libourne, France

Location

Centre Oscar Lambret

Lille, France

Location

CHG

Longjumeau, France

Location

Clinique des 4 pavillons

Lormont, France

Location

CHU Lyon Sud

Lyon, France

Location

CH Saint Joseph

Marseille, France

Location

CHU La Timone

Marseille, France

Location

Hôpital Européen

Marseille, France

Location

Hôpital Nord

Marseille, France

Location

CH

Mâcon, France

Location

Polyclinique du Val de Saône

Mâcon, France

Location

Hôpital Layné

Mont-de-Marsan, France

Location

CH

Montbrison, France

Location

CH

Montceau-les-Mines, France

Location

CH

Montélimar, France

Location

CHI Le Raincy Montfermeil

Montfermeil, France

Location

Centre Azuréen de Cancérologie

Mougins, France

Location

Hopital Americain de Paris

Neuilly-sur-Seine, France

Location

Polyclinique Val de Loire

Nevers, France

Location

Hôpital l'Archet II

Nice, France

Location

CHU Carémeau

Nîmes, France

Location

Clinique Valdegour

Nîmes, France

Location

CHR - Sce D'HGE

Orléans, France

Location

CHR - Sce d'Oncologie

Orléans, France

Location

Hôpital Privé Les Peupliers

Paris, France

Location

Hôpital Saint Louis

Paris, France

Location

CH

Pau, France

Location

Centre Catalan d'Oncologie

Perpignan, France

Location

Hôpital Saint Jean

Perpignan, France

Location

CHU Haut Lévèque

Pessac, France

Location

Polyclinique Francheville

Périgueux, France

Location

Centre Hospitalier Annecy Genevois

Pringy, France

Location

CH

Privas, France

Location

CHU Robert Debré

Reims, France

Location

Institut Jean Godinot

Reims, France

Location

CHU Pontchaillou

Rennes, France

Location

CH

Rodez, France

Location

CH Romans

Romans-sur-Isère, France

Location

CH Yves Lefoll

Saint-Brieuc, France

Location

CHPG

Saint-Chamond, France

Location

CH

Saint-Dié, France

Location

CHU

Saint-Etienne, France

Location

Polyclinique Côte Basque Sud

Saint-Jean-de-Luz, France

Location

Centre Joliot Curie

Saint-Martin-Boulogne, France

Location

Clinique de la Côte d'Opale

Saint-Martin-Boulogne, France

Location

Clinique Mutualiste de l'Estuaire - Cité Sanitaire

Saint-Nazaire, France

Location

Clinique

Sainte-Colombe, France

Location

Centre Médical National MGEN Alfred Leune

Sainte-Feyre, France

Location

CH

Semur-en-Auxois, France

Location

CH

Soissons, France

Location

Hôpital Broussais

St-Malo, France

Location

Centre Paul Strauss

Strasbourg, France

Location

Hôpital Sainte Musse

Toulon, France

Location

CH Gustave Dron

Tourcoing, France

Location

CH Trousseau

Tours, France

Location

CH

Valence, France

Location

CHBA

Vannes, France

Location

CH

Vernon, France

Location

CH

Vesoul, France

Location

CH Privé

Villeneuve-d'Ascq, France

Location

CH

Villeneuve-Saint-Georges, France

Location

CHU Clarac

Fort-de-France, Martinique

Location

Related Publications (1)

  • Lepage C, Phelip JM, Cany L, Faroux R, Manfredi S, Ain JF, Pezet D, Baconnier M, Deguiral P, Terrebone E, Adenis A, Le Malicot K, Bedenne L, Bouche O. Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer: The FFCD PRODIGE 13 randomised phase III trial. Dig Liver Dis. 2015 Jul;47(7):529-31. doi: 10.1016/j.dld.2015.03.021. Epub 2015 Apr 2. No abstract available.

    PMID: 25933809BACKGROUND

MeSH Terms

Conditions

Colorectal NeoplasmsColonic NeoplasmsRectal Neoplasms

Condition Hierarchy (Ancestors)

Intestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal Diseases

Study Officials

  • Come Lepage, Pr

    Centre Hospitalier Universitaire Dijon

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
FACTORIAL
Model Details: This study is a surveillance study not an interventional study with products
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 14, 2009

First Posted

October 15, 2009

Study Start

September 1, 2009

Primary Completion

December 1, 2019

Study Completion

June 1, 2021

Last Updated

December 7, 2021

Record last verified: 2021-12

Locations